Speed Kills: Advancement in Th17 Cell Adoptive Cell Therapy for Solid Tumors.

Steven N Fiering, Gregory W Ho

Cancer research 2020 Sep 15

filter terms:

IL6 is targeted as part of treatment in adoptive cell therapy (ACT) because of its protumor effects and its role in the cytokine release syndrome. However, another major role of IL6 is to polarize naïve CD4+ T cells from Tregs to Th17 cells. While Th17 T cells are associated with autoimmunity, they are present around many different solid tumor cancers and their role in tumor microenvironments is unclear. In this issue of Cancer Research, Knochelmann and colleagues show that Th17 cells with less in vitro expansion in IL6-driven Th17 ACT provide greater solid tumor control and robust immune memory, highlighting advancement in the field of ACT application to solid tumor immunotherapy.See related article by Knochelmann et al., p. 3920. ©2020 American Association for Cancer Research.

Citation

Steven N Fiering, Gregory W Ho. Speed Kills: Advancement in Th17 Cell Adoptive Cell Therapy for Solid Tumors. Cancer research. 2020 Sep 15;80(18):3795-3796